Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Mural Oncology Clinical Trials 781-614-0100 (US Only)
clinicaltrials@muraloncology.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
Back

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Recruiting

Open to: ALL

Age: 18.0 - N/A

London Manchester Oxford

Medical Conditions

Melanoma
Melanoma, Cutaneous Malignant

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2021 Jun 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Subcutaneous injection of nemvaleukin every 7 days

Intervention Arm Group : Advanced Cutaneous Melanoma Subcutaneous Dosing (Cohort 1);

Intervention Type : DRUG
Intervention Description : Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days

Intervention Arm Group : Advanced mucosal melanoma with IV Dosing (Cohort 2);

Intervention Type : DRUG
Intervention Description : Intravenous (IV) infusion over 30 minutes twice every 21 days (Day 1 and Day 8 dosing of a 21 day cycle)

Intervention Arm Group : Advanced Cutaneous Melanoma with Less Frequent IV Dosing (Cohort 3);Advanced Cutaneous Melanoma with Less Frequent IV Nemvaleukin Dosing + Pembrolizumab (Cohort 4);

Intervention Type : DRUG
Intervention Description : Cohort 4 only: 200mg IV pembrolizumab on Day 1 of a 21-day cycle

Intervention Arm Group : Advanced Cutaneous Melanoma with Less Frequent IV Nemvaleukin Dosing + Pembrolizumab (Cohort 4);



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Marsden Hospital
    London
    SW3 6JJ
  • The Christie Hospital
    Manchester
    M20 4BX
  • The Churchill Hospital
    Oxford
    OX3 7LE

Mural Oncology Clinical Trials 781-614-0100 (US Only)
clinicaltrials@muraloncology.com



The study is sponsored by Mural Oncology, Inc



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04830124
Last updated 27 June 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top